Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AAD 2025: Advancements in Dermatology : Episode 2
AAD 2025 Insights: Treatment Patterns in Moderate to Severe Psoriasis Patients on Biologics
A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable differences in treatment patterns, discontinuation rates, persistence, and adherence among psoriasis patients treated with different biologics including tildrakizumab, risankizumab, guselkumab, and ustekinumab, with implications for clinical decision-making based on early versus late disease onset and prior biologic exposure.
EP: 1.Tildrakizumab for Nail Psoriasis: Key Findings From AAD 2025
Now Viewing
EP: 2.AAD 2025 Insights: Treatment Patterns in Moderate to Severe Psoriasis Patients on Biologics
EP: 3.Adherence in Psoriasis Care: Barriers, Solutions, and the Road Ahead
EP: 4.Ruxolitinib Cream and Atopic Dermatitis at AAD 2025
EP: 5.JAK Inhibitors vs Cytokine Inhibitors: AAD 2025 Findings on Infection Risks
EP: 6.From AAD 2025 to the Future: Advancements in Dermatology to Watch
- Discuss the data presented at AAD 2025 on treatment patterns in patients with moderate to severe psoriasis treated with biologics.
- What were the objectives of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- n = 31521
- n = 338 receiving TIL
- n = 113 early onset (first diagnosis < 40 years)
- n = 225 late onset (first diagnosis ≥ 40 years)
- n = 94 use of ≥ 1 biologic in the pre-index period
- n = 14621 receiving RIS
- n = 5544 early onset (first diagnosis < 40 years)
- n = 9077 late onset (first diagnosis ≥ 40 years)
- n = 4520 use of ≥ 1 biologic in the pre-index period
- n = 10824 receiving GUS
- n = 3779 early onset (first diagnosis < 40 years)
- n = 7045 late onset (first diagnosis ≥ 40 years)
- n = 3994 use of ≥ 1 biologic in the pre-index period
- n = 5738 receiving UST
- n = 2098 early onset (first diagnosis < 40 years)
- n = 3640 late onset (first diagnosis ≥ 40 years)
- n = 2280 use of ≥ 1 biologic in the pre-index period
- Time to treatment discontinuation
- Treatment persistence
- Treatment adherence, defined as proportion of days covered
- n = 338 receiving TIL
- n = 31521
- Please provide your key takeaways from this study. What do you find significant about the treatment across agents concerning time to treatment discontinuation, persistence rates, and treatment adherence? How do you anticipate these trends will evolve in the future?
- In your practice, what are the rates of persistence and adherence to plaque psoriasis treatment, and what key factors influence these outcomes?
Related Videos
Related Content
Cefdinir Nearly Doubles Outpatient Uncomplicated UTI Treatment Failure Compared With Cephalexin
November 11th 2025Article
Cefdinir is linked to nearly double the outpatient uncomplicated UTI treatment failure of cephalexin, with higher recurrence and increased resistance to other cephalosporins.
Read More
